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Objective:  Given  the availability  of  extensive  digitized  healthcare  data  from  medical  records,  claims  and
prescription information,  it is  now  possible  to use  hypothesis-free,  data-driven  approaches  to  mine  medi-
cal databases  for novel  insight.  The  goal  of  this  analysis  was  to  demonstrate  the  use  of  artiﬁcial  intelligence
based  methods  such  as  Bayesian  networks  to open  up opportunities  for  creation  of new  knowledge  in
management  of chronic  conditions.
Materials  and  methods:  Hospital  level  Medicare  claims  data  containing  discharge  numbers  for  most
common  diagnoses  were  analyzed  in a hypothesis-free  manner  using  Bayesian  networks  learning
methodology.
Results:  While  many  interactions  identiﬁed  between  discharge  rates  of  diagnoses  using  this  data  set
are  supported  by  current  medical  knowledge,  a novel  interaction  linking  asthma  and  renal  failure  was
discovered.  This  interaction  is  non-obvious  and  had  not  been  looked  at  by the  research  and  clinical
communities  in  epidemiological  or clinical  data.  A  plausible  pharmacological  explanation  of  this link  is
proposed  together  with  a  veriﬁcation  of  the  risk  signiﬁcance  by  conventional  statistical  analysis.
Conclusion:  Potential  clinical  and  molecular  pathways  deﬁning  the  relationship  between  commonly  used
asthma  medications  and renal  disease  are  discussed.  The  study  underscores  the  need  for  further  epi-
demiological  research  to validate  this  novel  hypothesis.  Validation  will lead  to  advancement  in  clinical
treatment  of  asthma  & bronchitis,  thereby,  improving  patient  outcomes  and  leading  to  long term  cost
savings.  In summary,  this  study  demonstrates  that  application  of  advanced  artiﬁcial  intelligence  meth-
ods  in  healthcare  has  the  potential  to enhance  the  quality  of care  by discovering  non-obvious,  clinically
relevant  relationships  and  enabling  timely  care  intervention.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
In 1960 the United States spent 5.2% of gross domestic product
GDP) on healthcare and by 2004 that number has risen to 16%.
urrent predictions have healthcare expenditures exceeding 18.7%
f GDP today and forecast to increase to over 20% by 2025. There
s no doubt of a healthcare crisis unraveling in the United States
nd in other parts of the world, driven by the rapid increase in
he prevalence of chronic diseases such as diabetes and kidney dis-
ase. In addition to increasing prevalence of certain diseases, this
ncrease in health care costs can be attributed to new and pro-
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hibitively expensive therapeutics for cancer and other disorders,
and ever escalating costs of patient mismanagement and malprac-
tice. It is apparent that the returns from the current paradigm of
innovation in healthcare have diminished dramatically. Traditional
approaches of hypothesis driven clinical research are becoming
less effective in translating empirical data to successful health
outcomes. Given the rapid growth in the rates of accumulation
of healthcare data, every vertical of the global healthcare indus-
try from therapeutics research and development to epidemiology
and precision medicine would beneﬁt from data driven, unbiased
approaches. Mathematical and statistical tools developed in the
ﬁeld of artiﬁcial intelligence (AI) and machine learning are well
poised to assist clinical researchers in deciphering complex predic-
tive patterns in healthcare data.
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With government incentives offered to clinical organizations to
ransition from paper based patient information to well-structured
nd managed digital form, there has been a tremendous explosion
n the availability of patient-centric healthcare data. Such data can
e leveraged to open up new avenues in advancing healthcare by
mproving patient care and creating new efﬁciencies in delivering
are [1–4]. Understanding variation in treatment outcomes due to
atient speciﬁc molecular and clinical factors [5–7] is essential to
he practical implementation of and adoption of precision medicine
n clinical practice.
The predominant focus of the analytical efforts in health care
as been structured management and compilation of disparate data
odalities and data mining with the objective of testing hypotheses
enerated through reasoning. These efforts are limited by the cur-
ent thinking in medicine and biology, and often ignore unbiased,
bservational and “unknown biological” evidence. A data-driven
ypothesis generation approach creates a paradigm shift in health-
are by leading to discovery of new and often surprising trends in
linical outcomes. Identiﬁcation of non-obvious correlations and
ausal relationships may  lead to a signiﬁcant mitigation of side
ffects, need for additional medications, reduction of hospitaliza-
ions, decrease in unnecessary care, loss of income for patients, and
ventually in the overall change in clinical practice.
This study demonstrates how high-level, publicly available
ealthcare data, in particular, data coming from the United States
enters for Medicare and Medicaid Services (CMS) can be lever-
ged to generate profound and surprisingly powerful hypotheses in
atient management and disease outcome by employing advanced
earning methods such as Bayesian networks [8–13] (BNs). BNs
r Bayesian artiﬁcial intelligence is a mathematical framework for
earning probabilistic cause and effect relationships directly from
ata. The factor or variable relationships learned as directed acyclic
raphs. Learning BNs in large data sets is typically an NP-hard opti-
ization problem where an enormous number of possible graphs
re attempted in a heuristically driven process of ﬁnding locally
ptimal structures. In this case study, the Diagnosis Related Group
DRG) codes are the factors and the provider speciﬁc discharge
umbers are the observations.
The approach presented here is a data analytics pipeline devel-
ped to work with population claims data on the “big data” scale.
 network of cause and effect relationships between medical diag-
oses was learned in a purely data-driven manner from previously
ublished billing data from CMS. A follow up network analysis
evealed novel comorbidities, disease progression factors and the
equence of disease diagnoses for a number of chronic diseases. The
ndings were conﬁrmed by subsequent association-based statisti-
al analysis using logistic regression models. BNs are a powerful
ool that can be readily used in the analysis of big data and
resents a dynamic approach to the hypothesis driven epidemi-
logical research. These newly discovered non-trivial relationships
ight have a signiﬁcant impact on clinical disease management.
he increased utilization of technologies such as AI, in healthcare
esearch, is likely to have a signiﬁcant impact on clinical disease
anagement and global healthcare efﬁciency.
. Methods
The methods overview and the data analysis workﬂow are
hown in Fig. 1. Data was obtained from publicly released ﬁles from
he CMS  website [14]. Top 100 most frequently billed diagnosis
odes in the year of 2011 for a majority of healthcare providers in
he United States were assessed in the data along with the high
evel provider information, amount charged and amount paid to
he provider by the Medicare insurance plan. The wide discrep-
ncy of the provider charges across the United States had beenence in Medicine 74 (2016) 1–8
analyzed, presented, and discussed by the media [15–18]. The focus
of this analysis was  the relationship between the annual incidences
of diagnoses across the largest hospitals in the United States. In this
data set, the diagnosis of the discharged patients was represented
by the DRG codes. Fields containing information about the DRG
codes, total number of discharges in 2011 for each diagnosis and
the provider code were extracted from the dataset.
The initial step in the data processing workﬂow was  to orga-
nize the discharge count information as a data matrix of DRG codes
across provider codes. Next, the DRG codes missing in more than
70% of the providers were removed from further analysis along with
the provider codes not reporting any patient discharges for more
than 25% of the DRG codes in the data set. After the ﬁltering pro-
cedure, the dataset consisted of 100 DRG code discharges across
1618 hospitals. The total number of discharges for each provider
was used to normalize the number of discharges per a DRG code.
In the follow up analysis, it was  assumed in the case of a missing
data point that no patients were discharged with that diagnosis
code from the facility in 2011. Therefore, the remaining missing
data were imputed as zeros. Median polish normalization was per-
formed on the data matrix and the data was transformed to the
logarithmic scale. All data processing steps up to this point were
performed using R (http://www.r-project.org/) [19]. Details of data
processing are discussed in Supplementary ﬁle 1.
The processed and normalized data matrix was  analyzed using
the BN learner, bAIcisTM (Berg LLC, Framingham, Massachusetts,
U.S.A.). An ensemble of 20 BNs was  learned directly from the
data using stochastic optimization methods: Each network in the
ensemble was  created by optimizing the global network structure
with respect to the network Bayesian information criterion score
from graph families represented by a single linear regression model
with up to four regressors. Each DRG code was modeled as a node
in the network with the normalized number of discharges across
the provider data treated as the variable observations. A ﬁnal sum-
marized BN was  created by performing in silico interventions in
the ensemble for all learned node relationships [20]. Such simula-
tions are helpful in determining the strength of the cause and effect
link and reducing the number of spurious connections and cross-
correlations. In the ﬁnal step, a conﬁdence metric was assigned to
each reported structural relationship in the learned BN ensemble
based on the c-statistic measuring the difference in the poste-
rior distributions of the baseline and intervention data. Namely,
each driver node in a structural relationship was perturbed 10 fold
relative to its baseline mean a 1000 times for each of the ensem-
ble networks. The two posterior distributions for the dependent
node (the baseline and the perturbed) were compared using the
c-statistics or the area under the receiver operating characteristic
curve. Relationships in the resulting DRG code network ensemble
were retained if the strength of the connection measured by the c-
statistic was  larger than or equal to 0.8. Nodes representing related
DRG codes were combined. For example: DRG codes that only
vary based on presence of complicating conditions. The resulting
network ensemble was  visualized using Cytoscape (http://www.
cytoscape.org/) [21–23]. Table with results of simulation for the
selected sub network are shown in supplementary table A.
3. Results and discussion
The DRG code network learned from the CMS  data (Fig. 2a) con-
nected 61 DRG codes in a network of 178 connections. If two nodes
are connected in the network, it means that a change in the number
of discharges for one DRG code affects the number of discharges for
the second DRG code with the arrows indicating the directionality
of the cause and effect relationship. Interpretation of the meaning
of these connections depends on speciﬁc diagnoses involved. For
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cig. 2. (a) The panel shows the entire diagnosis code network with the selected sub
ach  node corresponds to a DRG code and edges show interactions between the D
T”  shaped connections indicate that number of diagnosis for the nodes are inverse
xample, when the source node is diabetes and the target node
s hypertension, the connection likely represents comorbidities at
 population level. When the source is diabetes and the target is
europathy, the connection likely represents complications from
isease.
Subnetworks centered on ‘heart failure & shock’ and ‘renal fail-
re’ were selected (Fig. 2b) for further exploration. These diagnoses
ere selected based on the cause of death index compiled by the
enters for Disease Control and Prevention [24]. According to this
eport, heart disease was the top cause of death in 2011. Kidney
elated conditions were ranked 9, 12, and 13. All renal conditions
ombined were noted as major causes of death. Therefore, the ‘heart
ailure’ and the ‘renal failure’ subnetworks were analyzed in detail.
he goal of the subnetwork analysis was to classify the connections
n the subnetwork as known or predicated on information in sup-
ort of the cause and effect already well established in the clinic, or
ovel with little to no reference in the scientiﬁc or medical litera-
ure. Presence of known connections in the networks demonstrates
hat relationships inferred statistically in a BN structure are valid
nd can be conﬁrmed by clinical or epidemiological research. Thus,
ovel connections can be considered to be the basis for formula-
ion of new hypotheses generated in a strictly data driven manner.
ased on the analysis it was found that many connections in the
heart failure’ and ‘renal failure’ subnetworks were known while
ovel interactions were also identiﬁed, in particularly, in the ‘renal
ailure’ subnetwork.
.1. Associations correlated by medical literatureHeart failure is a plurality of conditions that reduce the ability
f the heart to pump blood efﬁciently. These conditions include
ongenital heart defects, arrhythmias, coronary artery disease thatrk highlighted. (b) The panel shows the heart failure and renal failure subnetwork.
charge totals. The thickness of the arrow indicates the strength of the connection.
elated.
narrow arteries over time and high blood pressure that in com-
bination with heart muscle unable to effectively pump blood can
compromise the blood ﬂow in the body. The interaction between
‘heart failure and shock’ and ‘simple pneumonia and pleurisy’ was
removed from the subnetwork analysis because of inconsistencies
in the interaction between these diagnosis codes in the ensemble
of networks. Diagnosis relationships discovered from data in this
study within the ‘heart failure’ subnetwork are explored below:
3.1.1. Chronic obstructive pulmonary disease
Pulmonary hypertension is a well-established complication
observed in patients with chronic obstructive pulmonary disease.
In situations when the lungs try to compensate for low oxygen
concentration in blood due to inadequate lung ventilation, the com-
pensatory effect is the observed increase in blood pressure inside
the lungs. Increase in blood pressure inside the lungs (pulmonary
hypertension) leads to increased stress on the right ventricle that
can eventually cause heart failure.
3.1.2. Cardiac arrhythmia and conduction disorders
These disorders could result in heart failure. Therefore diagnosis
of heart failure correlates to diagnosis of causal conditions discov-
ered through the network. Based on output from the data analysis,
it can be surmised that potential increase in the number of heart
failure diagnoses will correspond to the increase in the number of
diagnoses of cardiac arrhythmias and conduction disorders in the
same patient population.3.1.3. Gastrointestinal hemorrhage
Heart failure can be a result of hypovolemic shock. Hypovolemic
shock occurs due to rapid loss of large blood volume that can result
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requent causes of hemorrhagic (hypovolemic) shock are trauma,
astrointestinal hemorrhage and organ injury.
.1.4. Renal failure
The link between anemia, cardiac problems and renal disease
s well known[25–27] and the challenges of treating patients with
ardio-renal insufﬁciencies are well documented [28]. About one-
ourth of the patients with renal disease have congestive heart
roblems and as renal disease worsens, the fraction of patients
ith heart disease increases to about 65–70% [25]. Large stud-
es have shown that worsening kidney disease is associated with
igher mortality and hospitalization rates in patients with previ-
us diagnosis of heart failure [29]. Thus, there is signiﬁcant evidence
upporting the relationship between heart failure and renal failure.
.1.5. Acute myocardial infarction
Heart failure is known to be a frequent complication of myocar-
ial infarction [30] and hence is a well-established connection. This
nteraction has been well studied through epidemiological studies
nd it is also known that the rate of heart failure after myocardial
nfarction decreases with time [31].
The diagnosis code corresponding to ‘renal failure’ in this anal-
sis encompassed chronic/acute kidney failure and other renal
isorders. Renal failure/insufﬁciency refers to reduction in the kid-
ey’s ability to remove waste products from blood. More than 10%
f adults 20 years or older have chronic kidney disease (CKD) [32]
he cost of treating CKD is very high because of the wide range of
omorbidities and quality of life factors [33]. One study showed that
he cost for treating end stage renal disease is continually increas-
ng and CMS  costs for this condition have reached 30 billion dollars
or 2009 [34]. Known medical relationships within the renal failure
ubnetwork are explored below:
.1.6. Kidney and urinary tract infections
This diagnosis code encompasses many types of renal infections
ncluding cystitis, abscess, lower and upper urinary tract infec-
ions. Recurrent or untreated urinary tract and kidney infections
re known to be linked with kidney scarring which contributes to
owered kidney function and renal failure [35–37].
.1.7. Disorders of nutrition, metabolism, and ﬂuids/electrolytes
Kidneys play an important role in maintaining the ﬂuid and elec-
rolyte balance. Therefore it is possible that a diagnosis of renal
ailure would lead to follow up tests and diagnosis of nutrition,
etabolism, ﬂuid and electrolyte balance problems.
.1.8. Simple pneumonia and pleurisy
It is established that chronic kidney disease increases suscep-
ibility to infections and that incidence of pneumonia in chronic
idney disease is a well documented infectious complication asso-
iated with kidney disease [38,39].
.1.9. Hypertension
Hypertension or high blood pressure is known to be the sec-
nd leading cause of kidney failure. It is thought that high blood
ressure damages blood vessels in the kidneys hence reducing the
bility of the kidneys to remove waste products from the blood [40].
The above investigation of the medical literature vis-à-vis the
ause and effect relationships discovered by the BN learner con-
rms the validity of application of the AI based mathematical
ethodology to data driven discovery of medical outcome patterns
rom high level billing data.ence in Medicine 74 (2016) 1–8
3.2. Discovery of a novel relationship in a patient population:
linking asthma to renal failure
The ‘renal failure’ DRG code was  inferred to interact with the
‘bronchitis and asthma’ diagnoses. There is limited information in
the medical literature that supports a direct link between incidence
of bronchitis/asthma and renal failure. Thus, the asthma and renal
failure relationship inferred from this study may  be considered a
novel discovery that can be linked to medication effects, disease
comorbidities or the order of diagnosis based on the dataset used in
the analysis. Speciﬁc diagnosis codes for this interaction were iden-
tiﬁed and a linear regression model was  built for these variables to
conﬁrm the BN ﬁnding and identify the signiﬁcance of the inter-
action. Signiﬁcant statistical association between the number of
renal failure diagnoses and the number of bronchitis/asthma diag-
noses was demonstrated by conventional statistical analysis in the
same data set with p-value of less than 1e-5 and the adjusted r2
of 25%. Moreover, the bronchitis/asthma factor was  signiﬁcant in
the multivariate linear regression model controlling for the other
predictors in Fig. 2b with p-value 0.0014.
In summary, a novel hypothesis was  generated in an entirely
data-driven manner: The incidence of renal failure may potentially
be associated with asthma or bronchitis, or perhaps the asthma
treatment strategies leading to a direct correlation of the number
of asthma/bronchitis discharges to the number of renal failure dis-
charges. Below is a summary description of the exploratory ﬁndings
in the scientiﬁc and medical literature potentially linking asthma
and renal failure.
3.3. Scientiﬁc evidence in support of the novel linkage between
asthma and renal failure
A clinical hypothesis and likely corresponding molecular mech-
anism is summarized in Fig. 3a and b summarizes potential
molecular mechanisms linking the effect of drugs used in the treat-
ment of bronchitis/asthma to their ability to potentially cause renal
dysfunction and/or renal failure. Below is a detailed description
highlighting the direct and indirect effect of 2-adrenergic ago-
nists on renal function and its potential to cause renal dysfunction
and/or renal failure.
Bronchitis and asthma are respiratory diseases where narrow-
ing of airways results in cough, shortness of breath, tightness in the
chest and wheezing. There are many choices of medication cur-
rently available to treat the symptoms as well as key pathways
involved in the etiology of asthma (Table 1). One of the oldest
and most widely used drug classes for symptomatic treatment
of asthma is 2-adrenergic agonists that are referred to as bron-
chodilators [41]. As shown in Table 1, 7 out of top 10 medications
used to treat asthma contain either a long acting or a short acting
2-adrenergic agonists. 2- adrenergic agonists interact with the
2 sub-type of the -adrenoceptors. Most 2-adrenergic agonist
bronchodilators in asthmatic patients are primarily administered
via use of a nebulizer to ensure maximal retention of the drug
within the lung environment, the primary site of action. However,
the rich vasculature within the lungs enables systemic absorp-
tion of the 2-adrenergic agonists [42]. Thus, the physiological and
pharmacological effect of 2-adrenergic agonists can be manifested
systemically in multiple organ systems including heart, skeletal
muscle, kidneys expressing receptors [42–44].
This study explores direct and indirect effects of 2-adrenergic
agonists that might potentially lead to renal dysfunction. Most of
the 2-adrenergic agonists used in treatment of asthma are primar-
ily removed from the circulation in the kidneys [45]. The kidneys
have widespread expression of the -adrenergic receptors within
the glomerulus and tubular epithelium inﬂuencing the hemody-
namics and electrolyte balance [46]. Electrolyte imbalances have
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Fig. 3. A mechanistic diagram supporting a novel hypothesis of the association between asthma medications and renal dysfunction. (a) Pathway in this panel was constructed
by  linking results published clinical research. (b) Potential molecular mechanism supporting the clinical ﬁndings. Protein abbreviations: Gs (guanine nucleotide-binding
regulatory protein), cAMP (cyclic adenosine monophosphate), PKA (protein kinase A), ACE (angiotensin converting enzyme inhibitor).
Table 1
Select clinical pharmacology of top 10 asthma drugs in 2011–12. Drug information was obtained from a drug index for prescription drugs [72]. Prescription count information









1. Singular 28,110 Montelukast sodium No No
2.  Proair HFA 23,931 Albuterol sulfate Yes (Short acting) Yes
3.  Advair Diskus 17,534 Fluticasone propionate and salmeterol Yes (Long acting) Yes
4.  Ventolin HFA 16,272 Albuterol sulfate Yes (Short acting) Yes
5.  Albuterol sulfate 13,978 Albuterol sulfate Yes (Short acting) Yes
6.  Spiriva Handihaler 9416 Tiotropium bromide monohydrate No No

















[8.  Symbicort 4962 Budesonide 
9.  Combivent 4251 Ipratropium
10.  Proventil HFA 4084 Albuterol su
een noted in asthma patients treated with 2-adrenergic ago-
ists [47,48]. The 2-adrenergic receptor has been demonstrated
o regulate the sodium linked transporter expression [49] and it
as been suggested that it is involved in salt sensitive hypertension
50]. Furthermore, -adrenergic receptors are known to inﬂuence
he synthesis and secretion of renin [51,52]. The fact that 2-
drenergic agonists do not undergo signiﬁcant biotransformation
rior to excretion suggests that the drugs could exert pharmaco-
ogical effects in the kidneys during the process of excretion.
One of the side effects associated with circulating 2-adrenergic
gonists such as albuterol is its ability to reduce circulat-
ng potassium levels and lead to hypokalemia [53–56]. Indeed,
ypokalemia is a well-deﬁned and often reported electrolyte imbal-
nce observed in asthmatic patients on 2-adrenergic agonists
53,56,57]. Persistent hypokalemia can lead to renal dysfunc-rmoterol fumarate dihydrate Yes (Long acting) Yes
ide and albuterol sulfate Yes (Short acting) Yes
Yes (Short acting) Yes
tion and tubulointerstitial diease. It has been shown that in rats,
hypokalemia induces renal injury [58,59] and, in humans, causes
renal failure [60]. In a study of 55 patients, it was  shown that chronic
hypokalemia was accompanied by renal cystogenesis that resulted
in scarring and other kidney damage leading to renal insufﬁciency
[61]. Other studies have also shown that hypokalemia in patients
with renal disease increased the rate of progression to end stage
renal disease and also increased the rate of mortality [62–64].
Other -adrenergic agonist effects on renal function include
their ability to inﬂuence renin release. Studies have demonstrated
that 2-adrenergic agonists tend to activate the renin-angiotensin
system (RAS) leading to increases in both the circulating plasma
renin and angiotensin II [51,52,65]. Literature documenting the role
of RAS inhibitor in conferring protection against chronic kidney dis-
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nduce hypokalemia, 2-agonists mediate increase in aldosterone,
nd consequently angiotensin II. Aldosterone is a key component
f RAS and leads to the adrenal gland secretion of angiotensin II
enerated within the RAS pathway. Activation of RAS and its com-
onents such as aldosterone and angiotensin II has been linked
o renal dysfunction [46,68]. This hypothesis is further substan-
iated by the observation that blocking of aldosterone function is
ssociated with improvement in kidney function [69].
The above evidence supports a role for 2 adrenergic ago-
ists in the potential etiology of renal failure in patients with
sthma. Indeed, there is recent evidence in the literature identi-
ying higher incidence of chronic kidney disease in patients with
sthma although the cause is unknown [70,71].
.4. Impact on healthcare economics and challenges
If the novel link between asthma medication and renal dys-
unction identiﬁed from this study is conﬁrmed through rigorous
pidemiological research, approximately 25% of the diagnoses of
sthma/bronchitis may  be associated with potentially undesirable
rug side effects in certain individuals. Further investigation and
odiﬁcation of treatment guidelines for asthma will not only lead
o better patient care but also to considerable cost savings given
he cost of annual treatment for a patient with end stage renal dis-
ase is estimated at around United States Dollar (USD) 70,000 [34].
urthermore, clinical intervention will result in signiﬁcant saving to
he CMS  that reimbursed USD 2.3 billion for the renal disease treat-
ent shown in the studied data across 3000 hospitals in the United
tates enrolled in the Inpatient Prospective Payment System.
Given that healthcare costs have been skyrocketing in the recent
ast and containing costs is one of the major concerns in public
ealth, new knowledge generated using methods such as those
resented in this paper are invaluable. Novel insights into treat-
ent complications using AI based methods will contribute to rapid
xpansion of medical knowledge and improvements in patient care.
.5. Future direction
The correlation identiﬁed in this study would not be readily
dentiﬁed in the current clinical research settings or analyses from
iterature. This is because the interaction between a treatment of
sthma and renal failure is non-obvious and is not currently subject
f widespread studies; there has been little evidence until recently
70,71].
Herein, we propose some future directions for this research. The
rst step would be to use patient level diagnosis and pharmacy
ata to further test this hypothesis. With patient level diagnosis
nformation, it will be possible to strengthen the link between diag-
osis of asthma and diagnosis of renal disease. Use of pharmacy
ata in addition to diagnosis information will enable gathering
ore evidence that 2-adrenergic agonist use is linked to loss
f renal function. A combination of diagnosis and pharmacy data
hould be to study the effect of blood pressure medication such
s non-speciﬁc -blockers and angiotensin converting enzyme
ACE) inhibitors. This interaction will provide another pathway to
trengthen the link between asthma drugs and renal complications
ince non-speciﬁc -blockers and ACE inhibitors have the reverse
ffect of 2-adrenergic agonists.
Validation of this hypothesis provides the foundation for incor-
orating routine checks on kidney function into the clinical
ractice for the treatment of asthmatic patients. Using longitu-
inal patient level data and genetic predisposition, one could
evelop a risk model to identify patients at high risk of renal
amage and divert those individuals to other treatment options
uch as corticosteroids, leukotriene modiﬁers, mast cell stabiliz-
rs, anticholinergics, and others. Such treatment strategies canence in Medicine 74 (2016) 1–8
be incorporated into the clinic, through clinical decision support
systems, by integrating patient electronic health records with a
knowledge base, to provide truly personalized patient care.
4. Conclusions
AI mathematical methodology is a powerful set of tools in data
science. The application of BNs to high level billing data from CMS
has demonstrated its utility in uncovering non-obvious relation-
ships in the data, in particular, a potentially critical interaction
between 2-adrenergic agonist asthma medications and renal dys-
function. This hypothesis generated purely from data gained more
validity after a thorough review of the relevant medical literature.
The review showed it is likely that the newly discovered causal
link is real. A conﬁrmatory epidemiological study is necessary to
implement this ﬁnding in clinical practice. Results presented in this
study lend strong support for the use of hypothesis free, data-driven
methodology in “big data” approaches to healthcare research and
management. Such methods are complementary to classical epi-
demiological research and may  be able to provide the researchers
with non-obvious and unconventional leads that are challenging
to focus on in a hypothesis driven experimental design and anal-
ysis. The new perspective presented here creates an opportunity
to make signiﬁcant progress in personalization of the treatment
pathways for some of the most prevalent diseases such as diabetes,
hypertension, congestive heart failure, and cancer. In conclusion,
the work presented here provides a rationale for employing use of
Bayesian artiﬁcial intelligence algorithms for the analyses of dis-
parate healthcare, socioeconomic, demographic, genetic, and even
data from wearables to advance medical research thereby improv-
ing patient outcomes and reducing treatment costs.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.artmed.2016.
11.001.
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